Scimar

Scimar

Growth Stage

Change How the World Prevents, Detects, And Treats Type 2 Diabetes

Change How the World Prevents, Detects, And Treats Type 2 Diabetes

Overview

Raised this Round: Raised: $358,639

Total Commitments ($USD)

Platform

Texture Capital

Start Date

12/20/2023

Close Date

Not Provided

Min. Goal
$99
Max. Goal
$55,000,000
Min. Investment

$99

Security Type

Equity - Common

Series

Series B

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$5.50

Pre-Money Valuation

$478,866,592

Year Founded

2009

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B2C

Margin

Medium

Capital Intensity

High

Location

Dauphin, Manitoba

Business Type

Growth

Scimar is raising funds on Texture Capital through Reg A+ crowdfunding. The company discovered the hepatalin hormone and is revolutionizing the prevention, diagnosis, and treatment of type 2 diabetes. Scimar is developing medical interventions based on the science of hepatalin to handle excess glucose in the body and bring an end to type 2 diabetes. The company has currently conceived four products, including SciMar NuPa Test, SciMar NuPa Daily, SciMar NuPa Renew, and Hepatalin-S, and plans to grow more. Dr. W. Wayne Lautt and Mick Lautt founded Scimar in 2009. The current crowdfunding campaign has a maximum target of $55 million. The campaign proceeds will be used for research and development, expanded infrastructure, cost of capital, facilities, operations, brand building, and accounting expenses.

Balance Sheet

Cash and Cash Equivalents

$170,892

Investment Securities

$534,916

Accounts and Notes Receivable

$1,750,342

Property, Plant and Equipment (PP&E)

$206,486

Property and Equipment

$206,486

Total Assets

$3,272,001

Accounts Payable & Accrued Liabilities

$1,614,373

Long Term Debt

$40,000

Total Liabilities

$14,985,567

Total Stockholders' Equity

$-11,713,566

Total Liabilities and Equity

$3,272,001

Statement of Comprehensive Income Information

Total Revenues

$3,028

Costs & Expenses Applicable to Rev

$136,728

Depreciation and Amortization

$209,181

Net Income

$-7,141,089

Earnings Per Share - Basic

$-0.12

Earnings Per Share - Diluted

$-0.12

Auditor: KPMG
Financials as of: 12/20/2023
Create a free account today to gain access to Kingscrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Scimar on Texture Capital 2024
Platform: Texture Capital
Security Type: Equity - Common
Valuation: $478,866,592
Price per Share: $5.50

Follow company

Follow Scimar on Texture Capital 2024

Buy Scimar's Deal Report

Warning: according to the close date for this deal, Scimar may no longer be accepting investments.

Scimar Deal Report

Get Kingscrowd's comprehensive report on Scimar including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Scimar is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Scimar deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge